Document is current
Any future updates will be listed below
-
Authors
Abdoul-Azize, Souleymane https://orcid.org/0000-0003-2065-9091
Hami, Rihab
Riou, Gaetan
Derambure, Céline https://orcid.org/0000-0002-6722-5955
Charbonnier, Camille
Vannier, Jean-Pierre
Guzman, Monica L. https://orcid.org/0000-0002-9262-8246
Schneider, Pascale
Boyer, Olivier https://orcid.org/0000-0002-7591-307X
- License Information
-
More Information
Article History
Received: 15 February 2023
Accepted: 15 May 2024
First Online: 29 May 2024
Competing interests
: S.A.A., J.P.V., and O.B. are designated as inventors for the European Patent application EP23307352 filed on December 22nd, 2023 in the names of Inserm, Université de Rouen, and CHU de Rouen and entitled “methods for preventing resistance to chemotherapy in acute lymphoblastic leukemia”. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. OB received research funding and/or honoraria from Argenx, BMS, CSL Behring, Egle Tx, OGD2, and UCB. M.G. received research funding from BridgeMedicines and holds equity of SeqRX. All other coauthors declare no competing interests.
